Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyschezia07.02.03.0050.000070%Not Available
Facial paresis17.04.03.0020.000035%
Central nervous system lesion17.02.10.0110.000087%Not Available
Exercise tolerance decreased08.01.03.0360.000087%Not Available
Post transplant lymphoproliferative disorder16.21.02.004; 11.05.10.006; 01.13.02.0040.000315%Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.000052%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000070%Not Available
Necrotising colitis07.08.01.0130.000070%Not Available
Conjunctival hyperaemia06.04.01.0040.000035%Not Available
Calciphylaxis14.04.01.0120.000140%Not Available
Gastrointestinal hypomotility07.02.02.0050.000052%Not Available
Anterior chamber flare06.04.10.0030.000035%Not Available
Eye pruritus06.04.05.0060.000105%Not Available
Ocular discomfort06.08.03.0080.000087%Not Available
Oesophageal rupture12.01.17.015; 07.04.05.0050.000052%Not Available
Diastolic dysfunction02.04.02.0220.000087%Not Available
Detachment of retinal pigment epithelium06.09.03.0110.000157%Not Available
Large intestinal haemorrhage24.07.02.026; 07.12.03.0030.000035%
Nerve injury17.02.10.007; 12.01.12.002--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000105%Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.000035%Not Available
Secretion discharge08.01.03.0190.000105%Not Available
Allodynia17.02.07.0170.000035%Not Available
Type IV hypersensitivity reaction10.01.03.0220.000035%Not Available
Growth retardation14.03.02.031; 15.03.05.016; 05.03.02.0070.000070%
Cerebral haematoma24.07.04.006; 17.08.01.0140.000035%Not Available
Nodule08.03.05.0020.000070%Not Available
Affect lability19.04.01.001--Not Available
Cardiac discomfort02.11.04.0010.000052%Not Available
Dental discomfort07.09.06.0020.000035%Not Available
The 24th Page    First    Pre   24 25 26 27 28    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene